Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: A proof of concept study

Pulmonary Pharmacology and Therapeutics

Volumn 29, Issue 2, 2014, Pages 233-240

  Tsushima, Kenji ^a,d   Yamaguchi, Koichi ^b   Kono, Yuta ^b   Yokoyama, Toshiki ^c   Kubo, Keishi ^c   Matsumura, Takuma ^d   Ichimura, Yasunori ^d   Abe, Mitsuhiro ^d   Terada, Jiro ^d   Tatsumi, Koichiro ^d  

^a Department of Orthopaedic Surgery Shinonoi General Hospital   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d CHIBA UNIVERSITY   (Japan)

Author keywords

Acute exacerbation of idiopathic pulmonary fibrosis; High mobility group box 1; Recombinant human soluble thrombomodulin; SpO2 FIO2; Thrombin antithrombin complex

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN DEGRADATION PRODUCT; FIBRINOLYTIC FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; KLEBS VON DER LUNGEN 6; LACTATE DEHYDROGENASE; PLASMIN ALPHA 2 PLASMIN INHIBITOR COMPLEX; SURFACTANT PROTEIN D; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN; THBD PROTEIN, HUMAN;

AGED; ARTICLE; ARTIFICIAL VENTILATION; CHLAMYDOPHILA PNEUMONIAE; CLINICAL ARTICLE; CONTINUOUS VENTILATOR; CONTROLLED STUDY; DISEASE EXACERBATION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; IDIOPATHIC DISEASE; KLEBSIELLA PNEUMONIAE; LUNG ASPERGILLOSIS; LUNG FIBROSIS; MALE; MORTALITY; MYCOPLASMA PNEUMONIAE; NONINVASIVE VENTILATION; OXYGENATION; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; SURVIVOR; THROMBOCYTE COUNT; ACUTE DISEASE; BLOOD; CLINICAL TRIAL; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; IDIOPATHIC PULMONARY FIBROSIS; LEUKOCYTE COUNT; PROSPECTIVE STUDY;

ACUTE DISEASE; AGED; C-REACTIVE PROTEIN; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; L-LACTATE DEHYDROGENASE; LEUKOCYTE COUNT; MALE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOMODULIN;

EID: 84922615009     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.04.008     Document Type: Article

References (26)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias: this joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002, 165:277-304.
2. Flaherty K.R., Travis W.D., Colby T.V., Toews G.B., Kazerooni E.A., Gross B.H., et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001, 164:1722-1727.
3. Nicholson A.G., Colby T.V., Dubois R.M., Hansell D.M., Wells A.U. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2001, 162:2213-2217.
4. Kondoh Y., Taniguchi H., Kawabata Y., Yokoi T., Suzuki K., Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathologic findings in three cases. Chest 1993, 103:1808-1812.
5. Yokoyama T., Tsushima K., Yamamoto H., Koizumi T., Kubo K. Potential benefits of early continuous positive pressure ventilation in patients with rapidly progressive interstitial pneumonia. Respirology 2012, 17:315-321.
6. Kim D.S., Park J.H., Park B.K., Lee J.S., Nicholson A.G., Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006, 27:143-150.
7. Agarwal R., Jindal S.K. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med 2008, 19:227-235.
8. Homma S., Sakamoto S., Kawabata M., Kishi K., Tsuboi E., Motoi N., et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med 2005, 44:1144-1150.
9. Kuhn C., Boldt J., King T.E., Crouch E., Vartio T., McDonald J.A. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989, 140:1693-1703.
10. Kubo H., Nakayama K., Yanai M., Suzuki T., Yamaya M., Watanabe M., et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005, 128:1475-1482.
11. Van de Wouwer M., Collen D., Conway E.M. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004, 24:1374-1383.
12. Ogawa Y., Yamakawa K., Ogura H., Kiguchi T., Mohri T., Nakamori Y., et al. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. JTrauma Acute Care Surg 2012, 72:1150-1157.
13. Johkoh T., Müller N.L., Cartier Y., Kavanagh P.V., Hartman T.E., Akira M., et al. Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology 1999, 211:555-560.
14. Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
15. Imokawa S., Sato A., Hayakawa H., Kotani M., Urano T., Takada A. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997, 156:631-636.
16. Ware L.B., Matthay M.A. The acute respiratory distress syndrome. NEngl J Med 2000, 342:1334-1349.
17. Mohri M., Gonda Y., Oka M., Aoki Y., Gomi K., Kiyota T., et al. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis). Blood Coagul Fibrinolysis 1997, 8:274-283.
18. Lum H., Malik A.B. Regulation of vascular endothelial barrier function. Am J Physiol Lung Cell Mol Physiol 1994, 267:L233-L241.
19. Cirino G., Cicala C., Bucci M.R., Sorrentino L., Maraganore J.M., Stone S.R. Thrombin functions as an inflammatory mediator through activation of its receptor. JExp Med 1996, 183:821-827.
20. Abeyama K., Stern D.M., Ito Y., Kawahara K., Yoshimoto Y., Tanaka M., et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. JClin Invest 2005, 115:1267-1274.
21. Shi C.S., Shi G.Y., Hsiao S.M., Kao Y.C., Kuo K.L., Ma C.Y., et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008, 112:3661-3670.
22. Van de Wouwer M., Plaisance S., De Vriese A., Waelkens E., Collen D., Persson J., et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. JThromb Haemost 2006, 4:1813-1824.
23. Nagato M., Okamoto K., Abe Y., Higure A., Yamaguchi K. Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med 2009, 37:2181-2186.
24. Abraham E., Arcaroli J., Carmody A., Wang H., Tracey K.J. Cutting edge. HMG-1 as mediator of acute lung inflammation. JImmunol 2000, 165:2950-2954.
25. Noth I., Anstrom K.J., Calvert S.B., de Andrade J., Flaherty K.R., Glazer C., et al. Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): a placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012, 186:88-95.
26. Park J.H., Kim D.S., Park I.N., Jang S.J., Kitaichi M., Nicholson A.G., et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007, 175:705-711.